AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2020
Mar 27, 2020
33148_dirs_2020-03-26_536566e1-32c1-4aeb-bce9-25bc0e2682a8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2020-03-24
Reporting Person: Shah Gaurav (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-24 | Common Stock | M | 90925 | $0.43 | Acquired | 1061642 | Direct |
| 2020-03-24 | Common Stock | F | 32645 | $13.78 | Disposed | 1028997 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-03-24 | Stock Option (Right to Buy) | $0.44 | M | 90925 | Disposed | 2020-12-15 | Common Stock (90925) | Direct |
Footnotes
F1: The options exercised and reported on this Form 4 were required to be exercised or otherwise forfeited in 2020 due to their upcoming expiration.
F2: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price and the tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of on this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer to cover the exercise price of the options and the tax liability,
F3: The option is fully vested and immediately exercisable and will expire under its own terms this year.